Search research articles
Contact Us
Filters
Showing results (31-40 of 68) with videos related to
Page
of 7
Sort By:
JCO Precision Oncology
|
February 21, 2022
Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review
Phillip J Hsu, Khushboo Singh, Ankit Dhiman, et al.
JCO Precision Oncology
|
November 20, 2020
Complete Response in a Patient With Chemorefractory <i>EGFR</i>-Amplified, PD-L1-Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti-PD-1 Monoclonal Antibody Therapy
Natalie Reizine, Bryan Peterson, Stephanie Moya, et al.
Cancer
|
January 16, 2019
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies
Manish R Sharma, Smita S Joshi, Theodore G Karrison, et al.
Annals of Surgical Oncology
|
January 9, 2021
Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy
Yaniv Berger, Mihai Giurcanu, Charles C Vining, et al.
Annals of Surgical Oncology
|
September 6, 2020
Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma
Yaniv Berger, Darryl Schuitevoerder, Charles C Vining, et al.
International Journal of Cancer
|
August 16, 2014
Tumor genome analysis includes germline genome: are we ready for surprises?
Daniel V T Catenacci, Andrea L Amico, Sarah M Nielsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 14, 2020
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
Daniel V T Catenacci, Drew Rasco, Jeeyun Lee, et al.
The Oncologist
|
September 26, 2022
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study
John D Powderly, Samuel J Klempner, Aung Naing, et al.
The Oncologist
|
June 29, 2019
<i>FGFR2</i>-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape
Samuel J Klempner, Russell Madison, Vivek Pujara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2014
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies
Ravi Salgia, Premal Patel, John Bothos, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 68) with videos related to
Sort By:
Page
of 7
JCO Precision Oncology
|
February 21, 2022
Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review
Phillip J Hsu, Khushboo Singh, Ankit Dhiman, et al.
JCO Precision Oncology
|
November 20, 2020
Complete Response in a Patient With Chemorefractory <i>EGFR</i>-Amplified, PD-L1-Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti-PD-1 Monoclonal Antibody Therapy
Natalie Reizine, Bryan Peterson, Stephanie Moya, et al.
Cancer
|
January 16, 2019
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies
Manish R Sharma, Smita S Joshi, Theodore G Karrison, et al.
Annals of Surgical Oncology
|
January 9, 2021
Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy
Yaniv Berger, Mihai Giurcanu, Charles C Vining, et al.
Annals of Surgical Oncology
|
September 6, 2020
Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma
Yaniv Berger, Darryl Schuitevoerder, Charles C Vining, et al.
International Journal of Cancer
|
August 16, 2014
Tumor genome analysis includes germline genome: are we ready for surprises?
Daniel V T Catenacci, Andrea L Amico, Sarah M Nielsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 14, 2020
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
Daniel V T Catenacci, Drew Rasco, Jeeyun Lee, et al.
The Oncologist
|
September 26, 2022
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study
John D Powderly, Samuel J Klempner, Aung Naing, et al.
The Oncologist
|
June 29, 2019
<i>FGFR2</i>-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape
Samuel J Klempner, Russell Madison, Vivek Pujara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2014
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies
Ravi Salgia, Premal Patel, John Bothos, et al.
Page
of 7